Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
Status:
Unknown status
Trial end date:
2019-08-29
Target enrollment:
Participant gender:
Summary
Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of
platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients.
However, current guidelines recommend ticagrelor 90 mg twice daily might not be suitable for
patients of Chinese. Therefore, the investigators performed this study to observe the
efficacy of 60-mg ticagrelor in comparison to 75-mg clopidogrel in Chinese patients with
stable CAD.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University